Vascular endothelial growth factor polymorphisms

Role in response and toxicity of tyrosine kinase inhibitors

Susan A J Vaziri, Jenny Kim, Mahrukh K. Ganapathi, Ram Ganapathi

Research output: Contribution to journalArticle

Abstract

Angiogenesis is central to the growth of normal tissues and tumors. Inhibiting this pathway has been a strategy for drug development for tumors not responsive to most agents used in chemotherapy. Notably, signaling mediated by vascular endothelial growth factor (VEGF) is a key target because aberrant signaling via this pathway is frequently associated with neoangiogenesis in tumors. The drug-discovery effort to blunt VEGF signaling has led to the approval of bevacizumab and several receptor tyrosine kinase inhibitors (TKIs) that have shown efficacy in the clinical management of breast, colorectal, lung, and kidney cancer. Understanding the genetic variability in VEGF and VEGF receptor has led to identifying genotypic variations (single nucleotide polymorphisms [SNPs]) associated with treatment outcome and toxicity. Notably, identification of SNPs in VEGF associated with angiogenesis inhibitor treatment-induced hypertension and outcome provides exciting opportunities for personalized medicine to improve outcome and reduced toxicity with these novel TKIs.

Original languageEnglish (US)
Pages (from-to)102-108
Number of pages7
JournalCurrent Oncology Reports
Volume12
Issue number2
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Single Nucleotide Polymorphism
Neoplasms
Precision Medicine
Vascular Endothelial Growth Factor Receptor
Angiogenesis Inhibitors
Kidney Neoplasms
Receptor Protein-Tyrosine Kinases
Drug Discovery
Colorectal Neoplasms
Lung Neoplasms
Breast Neoplasms
Hypertension
Drug Therapy
Growth
Pharmaceutical Preparations
Therapeutics

Keywords

  • Angiogenesis
  • Hypertension
  • Outcome
  • Toxicity
  • Tyrosine kinase inhibitors
  • VEGF polymorphism

ASJC Scopus subject areas

  • Oncology

Cite this

Vascular endothelial growth factor polymorphisms : Role in response and toxicity of tyrosine kinase inhibitors. / Vaziri, Susan A J; Kim, Jenny; Ganapathi, Mahrukh K.; Ganapathi, Ram.

In: Current Oncology Reports, Vol. 12, No. 2, 2010, p. 102-108.

Research output: Contribution to journalArticle

Vaziri, Susan A J ; Kim, Jenny ; Ganapathi, Mahrukh K. ; Ganapathi, Ram. / Vascular endothelial growth factor polymorphisms : Role in response and toxicity of tyrosine kinase inhibitors. In: Current Oncology Reports. 2010 ; Vol. 12, No. 2. pp. 102-108.
@article{f2e44c408b194f7ea6299404339f5ce2,
title = "Vascular endothelial growth factor polymorphisms: Role in response and toxicity of tyrosine kinase inhibitors",
abstract = "Angiogenesis is central to the growth of normal tissues and tumors. Inhibiting this pathway has been a strategy for drug development for tumors not responsive to most agents used in chemotherapy. Notably, signaling mediated by vascular endothelial growth factor (VEGF) is a key target because aberrant signaling via this pathway is frequently associated with neoangiogenesis in tumors. The drug-discovery effort to blunt VEGF signaling has led to the approval of bevacizumab and several receptor tyrosine kinase inhibitors (TKIs) that have shown efficacy in the clinical management of breast, colorectal, lung, and kidney cancer. Understanding the genetic variability in VEGF and VEGF receptor has led to identifying genotypic variations (single nucleotide polymorphisms [SNPs]) associated with treatment outcome and toxicity. Notably, identification of SNPs in VEGF associated with angiogenesis inhibitor treatment-induced hypertension and outcome provides exciting opportunities for personalized medicine to improve outcome and reduced toxicity with these novel TKIs.",
keywords = "Angiogenesis, Hypertension, Outcome, Toxicity, Tyrosine kinase inhibitors, VEGF polymorphism",
author = "Vaziri, {Susan A J} and Jenny Kim and Ganapathi, {Mahrukh K.} and Ram Ganapathi",
year = "2010",
doi = "10.1007/s11912-010-0085-4",
language = "English (US)",
volume = "12",
pages = "102--108",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Vascular endothelial growth factor polymorphisms

T2 - Role in response and toxicity of tyrosine kinase inhibitors

AU - Vaziri, Susan A J

AU - Kim, Jenny

AU - Ganapathi, Mahrukh K.

AU - Ganapathi, Ram

PY - 2010

Y1 - 2010

N2 - Angiogenesis is central to the growth of normal tissues and tumors. Inhibiting this pathway has been a strategy for drug development for tumors not responsive to most agents used in chemotherapy. Notably, signaling mediated by vascular endothelial growth factor (VEGF) is a key target because aberrant signaling via this pathway is frequently associated with neoangiogenesis in tumors. The drug-discovery effort to blunt VEGF signaling has led to the approval of bevacizumab and several receptor tyrosine kinase inhibitors (TKIs) that have shown efficacy in the clinical management of breast, colorectal, lung, and kidney cancer. Understanding the genetic variability in VEGF and VEGF receptor has led to identifying genotypic variations (single nucleotide polymorphisms [SNPs]) associated with treatment outcome and toxicity. Notably, identification of SNPs in VEGF associated with angiogenesis inhibitor treatment-induced hypertension and outcome provides exciting opportunities for personalized medicine to improve outcome and reduced toxicity with these novel TKIs.

AB - Angiogenesis is central to the growth of normal tissues and tumors. Inhibiting this pathway has been a strategy for drug development for tumors not responsive to most agents used in chemotherapy. Notably, signaling mediated by vascular endothelial growth factor (VEGF) is a key target because aberrant signaling via this pathway is frequently associated with neoangiogenesis in tumors. The drug-discovery effort to blunt VEGF signaling has led to the approval of bevacizumab and several receptor tyrosine kinase inhibitors (TKIs) that have shown efficacy in the clinical management of breast, colorectal, lung, and kidney cancer. Understanding the genetic variability in VEGF and VEGF receptor has led to identifying genotypic variations (single nucleotide polymorphisms [SNPs]) associated with treatment outcome and toxicity. Notably, identification of SNPs in VEGF associated with angiogenesis inhibitor treatment-induced hypertension and outcome provides exciting opportunities for personalized medicine to improve outcome and reduced toxicity with these novel TKIs.

KW - Angiogenesis

KW - Hypertension

KW - Outcome

KW - Toxicity

KW - Tyrosine kinase inhibitors

KW - VEGF polymorphism

UR - http://www.scopus.com/inward/record.url?scp=77952242619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952242619&partnerID=8YFLogxK

U2 - 10.1007/s11912-010-0085-4

DO - 10.1007/s11912-010-0085-4

M3 - Article

VL - 12

SP - 102

EP - 108

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 2

ER -